Science

Blocked From Selling Off-Brand Ozempic, Telehealth Startups Embrace a Less Effective Drug

After telehealth startups recently lost the ability to sell exact copies of patented GLP-1 weight-loss drugs, some firms have begun turning to a different, less effective medication that has been on the market in the United States since 2010. Often considered a precursor to blockbuster products like Novo Nordisk’s Ozempic …

Read More »

Dismantling NOAA Threatens the World’s Ability to Monitor Carbon Dioxide Levels

Even in the best of times, long-term observations can be very fragile. It is difficult to convince funding agencies to put money into long-term observations because, by definition, they are continuations; they have been done before. Most funding entities, from science agencies to philanthropic organizations, want to be associated with …

Read More »